60 Degrees Pharmaceuticals, Inc. (SXTP), a Washington, D.C.-based specialty pharmaceutical company listed on the Nasdaq Capital Market, develops medicines for infectious diseases, including the FDA-approved Arakoda (tafenoquine) for malaria prevention and an expanding pipeline into conditions such as babesiosis. The stock has been under intense pressure, closing near its 52-week low at roughly $0.59 per share, which makes the remaining $3.70 analyst price target a question of whether a beaten-down micro-cap can stage a multi-fold recovery.
SXTP does not currently have a meaningful multi-analyst consensus. The only actively maintained 12-month target identified is Ascendiant Capital's $3.70, issued by analyst Lucas Ward on May 22, 2026, alongside a Buy rating (lowered from $4.20). H.C. Wainwright, which had maintained higher targets—$6 in November 2025 and $24 as recently as January 2026—downgraded the stock to Hold on May 20, 2026 and removed its target. Because only one current, attributable target remains, this article uses that $3.70 figure as the central target while making clear it is a single analyst's view, not an analyst consensus. The historical spread—roughly $3.70 to $24—illustrates how dramatically expectations have contracted as the company diluted shareholders and its share price fell.
The latest verified closing price is approximately $0.5949 per share, after a sharp single-session decline of about 35%. The 52-week range spans $0.55 to $8.62, meaning the stock has already retraced nearly its entire prior advance. Reaching $3.70 from $0.59 would require about a 522% gain—an extremely large move. The company's financial profile is thin: trailing revenue near $1.1–$1.2 million, a trailing net loss of roughly $8 million, and negative EPS (earnings per share). With only about 3.5 million shares outstanding, a $3.70 price would imply a market value near $13 million before any further share issuance, a multiple of today's level but still a small absolute figure.
The core bull case rests on tafenoquine. Arakoda is already approved for malaria prevention, and 60 Degrees Pharmaceuticals has been pursuing additional indications, including babesiosis, which would expand its addressable market. Clinical or regulatory progress, positive trial data, or partnership announcements could re-rate a stock trading at a sub-$3 million market capitalization. The tiny float also means positive news can produce outsized percentage moves, and the $3.70 target reflects a scenario in which the company's pipeline advances and financing pressure eases.
The obstacles are substantial. The company is deeply unprofitable and cash-burning, and its share count has increased roughly 507% year over year, reflecting repeated equity and warrant-based financings. In November 2026 it announced a warrant inducement agreement that raised only about $526,000 at a $0.90 exercise price—capital that is quickly consumed. Continued dilution, missed earnings, pipeline delays, and the risk of Nasdaq listing-compliance issues all work against a recovery. The withdrawn H.C. Wainwright targets show that even covering analysts have turned cautious as fundamentals deteriorated.
Technically, SXTP trades below its 50-day moving average near $0.99 and its 200-day moving average near $1.73, signaling a sustained downtrend. The $0.55 area represents a key support level at the 52-week low, while prior congestion near $0.90–$1.00 now acts as resistance. Any meaningful move toward $3.70 would first require reclaiming those levels and the psychological $1.00 mark, a structural challenge given the stock's weak trend.
The $3.70 target reflects a typical 12-month research horizon. Key near-term events include the third-quarter 2026 earnings report expected around mid-November 2026, updates on cash runway and any new financing or dilution, tafenoquine clinical and regulatory milestones, and any analyst rating or target revisions. Given the stock's volatility and thin capitalization, investors should also watch share-count changes, which directly affect per-share valuation.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor positions, and spot shifting trends more efficiently—especially useful for high-volatility names like SXTP where rapid price changes demand timely attention.
Can 60 Degrees Pharmaceuticals reach $3.70? The question hinges on a single remaining analyst target from Ascendiant Capital and a required move of roughly 520%—an extraordinary ask for a company losing money, burning cash, and diluting shareholders at a rapid pace. The tafenoquine pipeline offers a genuine, if unproven, catalyst, and the stock's microscopic float could amplify any positive development. However, the withdrawal of H.C. Wainwright's targets and the stock's persistent slide below key moving averages underscore how much has to go right. Investors should treat the $3.70 figure as one firm's scenario, not a forecast or guarantee, and focus next on earnings, financing, and pipeline updates.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that SXTP and MLEC have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SXTP and MLEC's prices will move in lockstep.
| Ticker / NAME | Correlation To SXTP | 1D Price Change % | ||
|---|---|---|---|---|
| SXTP | 100% | -4.71% | ||
| MLEC - SXTP | 31% Poorly correlated | N/A | ||
| ACXP - SXTP | 26% Poorly correlated | -1.89% | ||
| KROS - SXTP | 26% Poorly correlated | +1.74% | ||
| IGC - SXTP | 26% Poorly correlated | -4.11% | ||
| MLYS - SXTP | 26% Poorly correlated | -1.83% | ||
More | ||||